30 July 2025
30 July 2025
CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.
Weak demand in China for MSD’s HPV vaccine Gardasil weighed down its Q2 revenue.
The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.
Key transactions this year emphasise the global demand for Korean biopharma innovation.
The approval is supported by strong preclinical data demonstrating MP1032's capacity to sustain muscle function.
Contract development and manufacturing organisation ViroCell Biologics has partnered AvenCell Therapeutics for expediting the development of new allogeneic chimeric antigen receptor (CAR)-T therapies to treat blood cancers.
Despite being significantly lower than the 200% rate threatened by Trump, the deal is set to ramp up drug costs by billions.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
